

Ossopan[®] 800

film-coated tablets

Therapeutic field

For the treatment of osteoporosis

Composition:

Each filmtab contains 830 mg Ossein hydroxyapatite compound.

Indications:

Osteoporosis of various origin: primary osteoporosis (pre-, peri-, postmenopausal, senile); secondary osteoporosis (due to: corticoid treatment, heparin treatment, immobilisation, rheumatoid arthritis, liver and kidney disease, hyperparathyroidism, osteogenesis imperfecta); early treatment of patients with an increased risk of osteoporosis. the product can also be used to regulate Ca/P balance during the pregnancy and lactation and to support fracture healing.

Dosage:

Osteoporosis: 2 filmtabs twice daily or as directed by the physician.

Other indications: 1-2 filmtabs daily.

Ossopan 800 should be taken with some liquid.

Contraindications:

Hypercalcemia and severe hypercalciuria; in patients with a predisposition to urinary concrements, the physician must decide on the dosage; in disorders of renal function, prolonged administration of high doses should be avoided; use in pregnancy has not provided evidence of any damage to the fetus.

Undisirable effects:

No side-effects specific to the product are known. Ossopan 800 is very well tolerated even when given for prolonged periods of time.

Interactions:

The absorption of iron and tetracyclines is reduced when Ossopan 800 is administered concomitantly since chelates are formed that are absorbed with difficulty. in such cases it is advisable to administer Ossopan 800 about 4 hours later.

Note:

Ossopan 800 contains only traces of Sodium chloride and is therefore suitable even for prolonged use in hypertensive patients

Packs:

20 Film coated tablets 800 mg



MINAPHARM
Under Licence of
Pierre Fabre Medicament
FRANCE

